Giving

Home

Scott Tomlins

Adjunct Associate Professor of Pathology
7322 CCC
734.763.8261
My research has focused on using high-throughput techniques to characterize the cancer genome and transcriptome to understand cancer biology and identify clinically relevant biomarkers and therapeutic targets. My most important contribution has been discovering and characterizing TMPRSS2:ETS gene fusions in prostate cancer. As a practicing genitourinary pathologist, I have led the translation of ETS gene fusions into diagnostic, early detection and subtyping biomarkers, and sign out our urine based MiProstate Score test. More recently, my research has focused on comprehensive characterization of the cancer genome through next generation sequencing (NGS), including the first comprehensive exome sequencing based study of lethal castration resistant prostate cancer (CRPC). My laboratory has also developed, validated and applied multiple targeted NGS approaches compatible with routine formalin fixed paraffin embedded (FFPE) tissue samples, including the combined DNA/RNA panel being used in the NCI sponsored MATCH trial, as well as approaches for cell free DNA (cfDNA), circulating tumor cells (CTCs) and urine specimens. We have extensively applied these approaches, including both targeted RNA and DNA sequencing, to prostate, kidney, bladder, adrenal, ovarian and penile cancers, as well as lymphomas, porocarcinomas, phyllodes tumors, and Merkel cell carcinomas. I have extensive expertise in both the histologic and molecular characterization of prostate cancer. For example, I serve as the central pathologist in an ongoing phase II study of enzalutamide in men eligible for active surveillance (AS) and led the first DNA/RNA profiling study of MRI guided AS biopsies demonstrating the ability to track clonality and progression in minute FFPE tissue specimens. My research has focused on using high-throughput techniques to characterize the cancer genome and transcriptome to understand cancer biology and identify clinically relevant biomarkers and therapeutic targets. My most important contribution has been discovering and characterizing TMPRSS2:ETS gene fusions in prostate cancer. As a practicing genitourinary pathologist, I have led the translation of ETS gene fusions into diagnostic, early detection and subtyping biomarkers, and sign out our urine based MiProstate Score test. More recently, my research has focused on comprehensive characterization of the cancer genome through next generation sequencing (NGS), including the first comprehensive exome sequencing based study of lethal castration resistant prostate cancer (CRPC). My laboratory has also developed, validated and applied multiple targeted NGS approaches compatible with routine formalin fixed paraffin embedded (FFPE) tissue samples, including the combined DNA/RNA panel being used in the NCI sponsored MATCH trial, as well as approaches for cell free DNA (cfDNA), circulating tumor cells (CTCs) and urine specimens. We have extensively applied these approaches, including both targeted RNA and DNA sequencing, to prostate, kidney, bladder, adrenal, ovarian and penile cancers, as well as lymphomas, porocarcinomas, phyllodes tumors, and Merkel cell carcinomas. I have extensive expertise in both the histologic and molecular characterization of prostate cancer. For example, I serve as the central pathologist in an ongoing phase II study of enzalutamide in men eligible for active surveillance (AS) and led the first DNA/RNA profiling study of MRI guided AS biopsies demonstrating the ability to track clonality and progression in minute FFPE tissue specimens.
Print

Affiliations: